NEW YORK, May 28 /PRNewswire/ -- The UltraPulse CO2 fractional laser was featured today on NBC's Today Show as an exciting and revolutionary new treatment for scars. During the broadcast, triplets who were severely burned in a fire as infants told their personal story and discussed recent treatments with the Lumenis UltraPulse laser. After only two treatments with the groundbreaking ActiveFX and DeepFX technologies, the triplets Jordan, Trae and Chandra Berns have achieved noticeable improvement in the appearance of their scars. The triplets' incredible story was also featured in the May issue of Glamour.
Dr. Kenneth Beer and Dr. Jill Waibel, the West Palm Beach physicians treating the triplets, are pioneers in the application of fractional lasers for the treatment of scars. They chose the Lumenis' UltraPulse system due to its dual-treatment modality.
"My objective when treating scars is two-fold: first, I ablate away portions of the scar by drilling micro-channels deep into the affected area, thereby eliminating part of the scar and enabling increased mobility and improved appearance. This treatment is known as DeepFX, and it serves to create new healthy tissue replacing the bulky scar tissue. Then, I use the ActiveFX treatment on the surface of the skin to smooth and even out the texture as well as remove any discoloration and unwanted pigmentation," explained Dr. Waibel. "This dual-treatment regimen is known as TotalFX, and it offers a unique inside out approach that can be applied to treating all scars including burn scars, acne scars, and traumatic injury scars."
"Dr. Beer and Dr. Waibel contacted Lumenis after the Berns sisters came to their Palm Beach office for a consultation. The doctors felt that the UltraPulse laser would be the ideal treatment choice for the triplets. Lumenis was very happy to support the extensive treatments that the Berns sisters required. We will continue to support innovative work treating traumatic scars with the UltraPulse system," added Robert Mann, General Manager Global Aesthetics and Dermatology at Lumenis.
Lumenis pioneered skin resurfacing over 18 years ago with its C02 lasers. The Lumenis UltraPulse laser system has FDA clearance for more than 34 indications and is referenced in excess of 90 peer-reviewed publications. Although frequently used for aesthetic applications, the UltraPulse offers 240 watts of power and microsecond pulses which combined provide a broad canvas from which other treatments in cutaneous surgical and aesthetic applications can be provided.
"With its Aesthetic, Surgical and Ophthalmic divisions, Lumenis has the unique advantage to offer physicians novel applications to bridge the gap between surgical and aesthetic treatments," commented Dov Ofer, CEO of Lumenis. "Dealing with burn scars is an excellent example of how a premium laser such as our UltraPulse system, when used extensively in surgical and aesthetic applications in the hands of leading physicians, can drive new treatments and offer hope to people around the world."
The entire story of the Berns triplets and their treatments using the UltraPulse Fractional CO2 laser can be found at www.bernstriplets.com.
Lumenis is Israel's largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, presence in over 100 countries worldwide, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto www.lumenis.com.
Lumenis(R) is a registered trademark of Lumenis Ltd. UltraPulse(R) is a trademark of Lumenis Ltd.
Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.
Contacts: Charly Rok Lippe Taylor Office: 212-598-4400 x155 Cell: 917-912-2863 email@example.com Michelle Maydan Director of Corporate Communications Lumenis Toll-free: 1-866-569-0597 Office: +972-4-959-9004 firstname.lastname@example.org
Copyright©2009 PR Newswire.
All rights reserved